Hikma Pharmaceuticals Plc AGM Update (4929I)
02 April 2020 - 5:00PM
UK Regulatory
TIDMHIK
RNS Number : 4929I
Hikma Pharmaceuticals Plc
02 April 2020
Hikma Pharmaceuticals PLC - AGM Venue
London, 2 April 2020 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ( Hikma ), following due consideration and given the
recent guidance from the Investment Association, GC100 and others
relating to the holding of general meetings, is to change the venue
for its Annual General Meeting ('AGM').
The meeting will now be held at 22 Regent Road, Surbiton KT5
8NL. As two shareholders reside at this address and the government
has forbidden public meetings of more than two people, no
additional shareholders will be admitted. The time and date remain
unchanged at 10.00 am on Thursday 30 April 2020.
As previously announced, shareholders will still be able to
listen remotely and to submit their proxy forms and any questions
in advance of the meeting. Please see 'Remote Attendance', below,
for further details.
The Board encourages shareholders to monitor the Company's
website and regulatory news services for any updates in relation to
the AGM that may need to be provided and encourages shareholders to
submit their proxies as early as possible, as the situation
continue to change. Should shareholders have any questions, please
contact the Company Secretary at cosec@hikma.uk.com
Remote Attendance
Shareholders may not attend the meeting in person. Shareholders
may listen to the meeting remotely. Please be aware that such
remote listening is at the discretion of the AGM Chairman and
connectivity cannot be guaranteed. Shareholders listening remotely
will not be counted as being present at the meeting and, therefore,
will not be able to vote at the meeting and will not have the
ability to speak or ask questions. Shareholders listening remotely
are encouraged to do the following in advance of the meeting:
1. Lodge your proxy votes with the registrar (
www.hikmashares.com ) in accordance with the instructions contained
in the Notice of AGM which has separately been made available to
shareholders - these will be counted in the votes for the
meeting
2. Submit any questions to the Company Secretary (
cosec@hikma.uk.com ) - these questions will be answered at the
meeting in the normal way
Telephone
1. Dial the appropriate telephone number from the list below
a. Jordan: +96265802909
b. UK: +442038924456
c. US: +16142414100
d. Other international numbers available: https://hikma.zoom.us/zoomconference
2. Enter the meeting ID (577 822 004) followed by #.
3. There is no participant ID, therefore, press #.
4. You will automatically be placed on mute and will not be able to speak
Web-Based Access
1. Open a web browser, ideally Chrome
2. Enter the web address https://hikma.zoom.us/j/577822004
3. Choose to 'Join with Computer Audio'
4. You will automatically be placed on mute and will not be able to speak
Skype Access
1. Open a web browser
2. Enter the web address https://hikma.zoom.us/skype/577822004
3. Choose to 'Join Zoom Meeting'
4. You will automatically be placed on mute and will not be able to speak
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399
2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
FURIBMRTMTMMBTM
(END) Dow Jones Newswires
April 02, 2020 02:00 ET (06:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024